MarketLens
Sign Up

J&J's Insider Sales: Opportunistic Diversification, Not a Litigation Warning

3 months ago
SHARE THIS ON:

J&J's Insider Sales: Opportunistic Diversification, Not a Litigation Warning

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 months ago

Industrial Giant Sees Insider Selling, According to Latest SEC Filing

An industrial giant insider sold 7,669 shares for ~$1.3 million at $171.20 per share, cutting his direct stake by 15%, per the latest SEC filing.
Stock News•3 months ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson will pay ~$5.5B to settle ~76,000 talc lawsuits alleging baby powder caused ovarian cancer, removing a major legal overhang.
Stock News•4 months ago

Members of Congress Are Loading Up on Johnson & Johnson and UnitedHealth. Here's Why Retail Investors Should Pay Attention.

Congress members are buying Johnson & Johnson and UnitedHealth stock, signaling potential insider confidence in the healthcare sector.

Breaking News

View All →

Top Headlines

View More →
Stock News•24 minutes ago

5 Bullish Signs the AI Rally is Back on Track

Stock News•37 minutes ago

Jensen Huang joins list of high-profile founders ousted from their own companies

Stock News•42 minutes ago

Nvidia's financing web raises new risks after Jensen Huang's exit

Stock News•52 minutes ago

Jensen Huang Is Out at Nvidia

Stock News•57 minutes ago

Nvidia's board and ex-CEO Jensen Huang are a clown show — why the sorry spectacle likely isn't over